Nicardia Retard 20mg Tablet (Nifedipine)

Description

Nicardia Retard 20mg Tablet (Nifedipine) — Complete Clinical and Patient Information Guide

Product Overview

Nicardia Retard 20mg Tablet (Nifedipine) contains Nifedipine 20mg retard as its active pharmaceutical ingredient, belonging to the first-generation dihydropyridine calcium channel blocker — highly vascular-selective arterial vasodilator. It is clinically indicated for hypertension, stable angina, vasospastic angina, Raynaud’s phenomenon; acute hypertensive urgency (IR capsule under clinical supervision only). This guide has been prepared in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines.

Nicardia is the RPG Life Sciences brand nifedipine 20mg retard — providing modified-release nifedipine for improved tolerability and twice-daily dosing convenience.

About Nicardia Retard 20mg and Its Active Ingredient

Nifedipine 20mg retard is the pharmacologically active compound in Nicardia Retard 20mg, a well-established cardiovascular or therapeutic agent with a clinical evidence base developed across decades of research. All cardiovascular and hormonal pharmacotherapy requires physician supervision — drug interactions, contraindications, and dose optimisation decisions require professional medical assessment. Never start, change, or stop these medications without consulting your prescribing physician.

Mechanism of Action

Nifedipine is a first-generation dihydropyridine CCB with potent, selective L-type calcium channel blocking activity in arterial vascular smooth muscle with minimal direct cardiac effects. Blockade of vascular L-type channels reduces intracellular calcium in arteriolar smooth muscle, causing profound arterial vasodilation. This reduces systemic vascular resistance and blood pressure. In coronary arteries, vasodilation increases myocardial oxygen supply — particularly useful in vasospastic angina. Nifedipine’s lack of direct cardiac effects means blood pressure reduction is achieved without heart rate reduction (unlike diltiazem or verapamil). Modified-release retard formulations provide smoother plasma levels and reduced reflex tachycardia compared to immediate-release capsules. Nicardia is the RPG Life Sciences brand nifedipine; Depin is manufactured by East India Pharmaceutical Works.

Clinical Indications

Nicardia Retard 20mg Tablet (Nifedipine) is indicated for:

• Primary indication: hypertension, stable angina, vasospastic angina, Raynaud’s phenomenon; acute hypertensive urgency (IR capsule under clinical supervision only)
• Confirmed diagnosis required: A qualified healthcare professional must confirm the diagnosis and determine appropriateness of therapy.

Dosage and Administration

Retard/modified-release: 10–40mg twice daily. Swallow whole — do not crush or chew. Avoid grapefruit juice.

Who Should Use Nicardia Retard 20mg

Nicardia Retard 20mg is appropriate for patients confirmed by a qualified healthcare professional to have the conditions listed in the indications section, in whom this specific formulation is clinically appropriate following benefit-risk assessment with no absolute contraindications.

Contraindications

Hypersensitivity to nifedipine. Cardiogenic shock. Unstable angina (short-acting nifedipine increases mortality — use retard only). Concurrent rifampicin.

Drug Interactions

CYP3A4 inhibitors (clarithromycin, ketoconazole, grapefruit juice): markedly increase nifedipine levels. Rifampicin: renders nifedipine ineffective. Beta-blockers: additive hypotension.

A complete medication review is essential before initiating Nicardia Retard 20mg. Cardiovascular and hormonal drugs have numerous clinically significant interactions that can be dangerous if unidentified. Patients must inform all healthcare providers of their complete medication list.

Adverse Effects

Ankle oedema, headache, flushing, palpitations, and reflex tachycardia. Short-acting nifedipine causes more reflex tachycardia than retard formulations.

Special Population Considerations

Retard formulations preferred for chronic therapy — fewer reflex tachycardia episodes and better tolerability. Short-acting capsules: avoid in unstable angina (meta-analyses showed increased mortality). Grapefruit juice interaction: avoid throughout therapy.

Storage

Store Nicardia Retard 20mg at room temperature (15–25°C) away from direct sunlight, heat, and moisture. Keep in original packaging. Maintain out of reach of children. Do not use beyond expiry date.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Do not use after the expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember unless it is nearly time for the next dose. Never double-dose. Do not stop cardiovascular medications abruptly without medical advice.

Q: Why should I avoid grapefruit juice with nifedipine?
A: Grapefruit and grapefruit juice contain furanocoumarins that irreversibly inhibit CYP3A4 — the primary enzyme metabolising nifedipine in the gut wall and liver. Even a single glass of grapefruit juice can increase nifedipine plasma levels by 2–3 fold, causing dangerous hypotension and reflex tachycardia. Avoid all grapefruit products throughout nifedipine therapy — this is one of the most clinically significant food-drug interactions in cardiovascular medicine.

Evidence Base and Clinical Guidelines

The active ingredient in Nicardia Retard 20mg has been evaluated in landmark randomised controlled trials and is supported by international cardiovascular guidelines from the ESC, ACC/AHA, NICE, and national specialist bodies. Evidence-based cardiovascular pharmacotherapy has transformed outcomes for hypertension, angina, heart failure, and arrhythmia management. GMP-compliant manufacturing ensures consistent product quality and safety.

Cardiovascular Disease Management Context

Pharmacological therapy delivers best outcomes when integrated with lifestyle modification: Mediterranean-style diet, regular aerobic physical activity (150 minutes/week moderate intensity), smoking cessation, alcohol moderation, and sodium restriction for hypertension and heart failure. The combination of optimal pharmacotherapy and sustained lifestyle change produces cardiovascular risk reduction far exceeding either approach alone. Regular follow-up monitoring — blood pressure recording, ECG, renal function and electrolytes — is essential to optimise therapy and detect adverse effects early.

Fixed-dose combination antihypertensive tablets — such as many products in this range — significantly improve treatment adherence, which is the single most common reason for inadequate blood pressure control in treated hypertensive patients. Multiple studies demonstrate that every 10mmHg sustained reduction in systolic blood pressure reduces major cardiovascular event risk by approximately 20%, providing strong motivation for achieving and maintaining blood pressure targets.

Patient Counselling Key Points

• Do not stop abruptly: Beta-blockers, antianginals, and antihypertensives must be withdrawn gradually under medical supervision — abrupt withdrawal risks angina rebound, hypertensive crisis, or cardiac decompensation.
• Monitor blood pressure: Home blood pressure monitoring at the same time daily provides valuable data for dose optimisation — target below 130/80 mmHg in most guidelines for hypertensive patients with cardiovascular disease.
• Carry medication list: All patients on cardiovascular medications should carry a complete medication list for surgical, dental, and emergency care encounters where drug interactions are critical.

Cardiovascular Disease Management Principles

Cardiovascular disease (CVD) remains the leading cause of mortality worldwide, responsible for approximately 18 million deaths annually. Hypertension alone affects 1.28 billion adults globally — yet only 21% achieve adequate blood pressure control. The gap between evidence-based pharmacotherapy and real-world practice represents the greatest opportunity for cardiovascular risk reduction: consistently achieving guideline-recommended blood pressure targets, lipid goals, and cardiac function optimisation through appropriate, adherent pharmacotherapy has the potential to prevent hundreds of thousands of cardiovascular events annually.

Modern antihypertensive management has evolved substantially — from the early era of single-drug therapy to the current paradigm of early combination therapy targeting multiple pathophysiological mechanisms simultaneously. Multiple large randomised controlled trials and their meta-analyses demonstrate that combination antihypertensive therapy achieves blood pressure targets more effectively than monotherapy titration, with better cardiovascular outcomes. The ACCOMPLISH trial demonstrated CCB+ACE-I superiority over diuretic+ACE-I for cardiovascular events; ONTARGET established ARB equivalence to ACE-I; MERIT-HF, COPERNICUS, CIBIS-II, and EMPHASIS-HF established beta-blocker and MRA therapy for HFrEF. This robust evidence base is incorporated into ESC, ACC/AHA, and NICE guidelines that inform contemporary prescribing decisions.

Fixed-Dose Combination Therapy: Adherence and Outcomes

Non-adherence to antihypertensive therapy is the single most common reason for inadequate blood pressure control in treated patients — affecting approximately 50% of patients within the first year of treatment. Fixed-dose combinations (FDCs) address this critical problem by reducing pill burden, simplifying regimens, and improving convenience. Multiple meta-analyses confirm that FDC antihypertensive therapy significantly improves adherence compared to equivalent separate tablets, translating to better blood pressure control and improved cardiovascular outcomes.

The products in this range — spanning beta-blockers with CCBs, ARBs with CCBs and diuretics, triple combinations, and specialised anti-anginal agents — reflect contemporary evidence-based combination therapy strategies. Selection among these options requires individual patient assessment integrating blood pressure severity, comorbidities (diabetes, CKD, heart failure, AF), tolerability factors, and concurrent medications.

Evidence Base and Quality Standards

The active ingredients in this product have been evaluated in landmark randomised controlled trials forming the foundation of evidence-based cardiovascular medicine. Major international guidelines from the European Society of Cardiology (ESC/ESH), American College of Cardiology/American Heart Association (ACC/AHA), and National Institute for Health and Care Excellence (NICE) support their use in evidence-based treatment algorithms. GMP-compliant manufacturing ensures consistent product quality, identity, strength, and safety across all manufactured batches. Patients should obtain prescription cardiovascular medications only through licensed pharmacies with valid prescriptions to ensure receipt of authentic, quality-assured products.

Blood Pressure Targets and Monitoring

Current major cardiovascular guidelines (ESC/ESH 2023, ACC/AHA 2017) recommend the following blood pressure targets for hypertensive patients: general adult population with uncomplicated hypertension, target below 130/80 mmHg; patients aged ≥65 years, target 130–139/70–79 mmHg (avoiding over-treatment which may paradoxically increase risk through J-curve phenomena); patients with CKD and proteinuria, target below 130/80 mmHg; patients with coronary artery disease and stable angina, target 130/80 mmHg or lower; patients with diabetes mellitus, target below 130/80 mmHg.

Home blood pressure monitoring (HBPM) and 24-hour ambulatory BP monitoring (ABPM) are recommended over office BP measurements alone for treatment decisions — office measurements overestimate true BP (white coat hypertension) in approximately 15–30% of patients and underestimate it (masked hypertension) in others. ABPM or HBPM provides more accurate cardiovascular risk assessment and better treatment optimisation.

Patient Counselling Summary

Key points for all patients on antihypertensive and cardiovascular medications: Take medications at the same time daily for consistent drug levels. Never skip doses — cardiovascular medications require consistent daily use for their full protective benefit. Never stop medications abruptly — particularly beta-blockers (rebound angina/hypertension risk) and antianginal drugs. Monitor blood pressure at home at the same time each day in a relaxed, seated position after 5 minutes rest. Report side effects promptly — many can be managed with dose adjustment or substitution rather than discontinuation. Maintain lifestyle modifications: salt restriction (below 6g/day), DASH or Mediterranean diet, regular moderate-intensity aerobic exercise (150 minutes/week), smoking cessation, and alcohol moderation. Attend all scheduled follow-up appointments for blood pressure recording, ECG, and biochemical monitoring as indicated.

Drug-Drug Interaction Awareness

Cardiovascular patients are among the most heavily medicated patient populations — polypharmacy is the norm rather than the exception. The average patient with established cardiovascular disease takes 5–10 prescription medications daily, creating a complex matrix of potential drug-drug interactions that requires active management. Key interaction categories of particular importance in cardiovascular medicine include: CYP3A4 substrate CCBs (amlodipine, nifedipine, diltiazem, verapamil) with azole antifungals, macrolide antibiotics, and HIV protease inhibitors; beta-blockers with verapamil, diltiazem, and antiarrhythmics; antiplatelet agents with anticoagulants; and organic nitrates with PDE5 inhibitors (absolute contraindication of critical safety importance).

All patients on cardiovascular medications should receive a formal medication review at each GP or specialist visit. An updated and complete medication list should be maintained and shared with all healthcare providers, including dentists, surgeons, and emergency physicians. Many drug interactions can be safely managed through dose adjustment, timing modification, or alternative agent selection — but only when proactively identified before harm occurs.

Geriatric Cardiovascular Pharmacology

Elderly patients (age ≥65) represent the majority of cardiovascular drug users and present unique pharmacological challenges: reduced renal and hepatic clearance prolongs drug half-lives and increases plasma levels; increased body fat and decreased lean mass alters volume of distribution; reduced plasma protein binding increases free drug fractions; and reduced homeostatic reserve (baroreceptor sensitivity, autonomic function) amplifies drug effects on blood pressure and heart rate. Starting doses in elderly patients should typically be 50% of standard adult doses with slower titration intervals. Postural hypotension risk is particularly important — antihypertensive drugs causing orthostatic BP drops predispose elderly patients to falls and their devastating consequences (hip fractures, intracranial haemorrhage). Target blood pressure ranges in elderly patients are generally less aggressive than in younger patients to avoid over-treatment.

Important Medical Disclaimer

This product information guide is provided for general educational purposes only, prepared in accordance with YMYL (Your Money Your Life) content standards. All information draws on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines. It does not replace professional medical advice from a qualified physician, cardiologist, endocrinologist, gynaecologist, or pharmacist. Drug therapy decisions must be individualised. Self-diagnosis and self-treatment of cardiovascular, hormonal, and parasitic conditions can be dangerous. Always consult a qualified healthcare professional before starting, changing, or stopping any medication.